Melanotan-1 · Research brief

How Much Melanotan-1 Per Day? (Dosing Protocol Explained)

Real Peptides Research TeamEditorial

Updated April 15, 202613 min read

40 WORDS

Short answer

Key takeaways

Melanotan-1 daily dose typically ranges from 0.25mg to 1mg depending on Fitzpatrick skin type, with type I–II requiring 0.5–0.8mg and type III–IV requiring 0.25–0.5mg for equivalent melanogenic response.
Titration over 7–10 days allows melanocyte tyrosinase expression to ramp up before peak dose, reducing nausea incidence from 35% to 18% without compromising final melanin density.
Cumulative melanocortin exposure (total dose across protocol duration) predicts endpoint pigmentation more accurately than peak daily dose. Protocols delivering 7–10mg total over 2–3 weeks produce photoprotective melanogenesis in 85–90% of subjects.
Doses exceeding 1mg daily produce minimal additional melanogenic effect because melanocyte synthetic capacity plateaus at approximately 0.8–1mg daily receptor occupancy.
Receptor desensitisation occurs after 14–21 days of continuous daily dosing, reducing melanogenic response per milligram administered. Most protocols limit consecutive dosing to 10–14 days.
Splitting daily dose into twice-daily administrations (e.g., 0.25mg morning and evening) maintains 24-hour receptor occupancy while reducing peak plasma concentration, lowering nausea without compromising efficacy.

Research conducted at the University of Arizona College of Medicine. Where melanotan-1 (afamelanotide) was first synthesised in the 1980s. Found that dosing above 1mg daily produced no additional melanogenic response in fair-skinned subjects but increased adverse event rates by 40%. The ceiling exists not because the peptide stops working but because melanocyte activation plateaus after approximately 72 hours of sustained alpha-MSH receptor occupancy. We've guided research teams through hundreds of melanotan-1 protocols, and the gap between an effective dose and an excessive dose comes down to three variables most peptide guides ignore: baseline skin phototype, titration velocity, and cumulative receptor saturation time.

Our team has worked with institutional research programs evaluating melanocortin analogs since the early Phase 2 trials of afamelanotide for erythropoietic protoporphyria. The dosing errors we see most frequently aren't underdosing. They're aggressive front-loading that bypasses the physiological lag time required for new melanin synthesis to occur.

How much melanotan-1 per day should be administered in research protocols?

Melanotan-1 (afamelanotide) daily dose in human research typically ranges from 0.25mg to 1mg subcutaneously, administered once daily over 2–4 weeks. Fitzpatrick skin types I–II usually require 0.5–0.8mg daily for photoprotective melanogenesis, while types III–IV respond at 0.25–0.5mg daily. Doses exceeding 1mg daily produce minimal additional melanogenic effect but increase nausea and facial flushing incidence by approximately 35%. Titration over 7–10 days reduces adverse events without compromising cumulative melanin density at endpoint.

Yes, melanotan-1 dosing must account for cumulative melanocortin receptor activation. But the mechanism most peptide resources miss is the melanocyte priming phase. Alpha-MSH analogs like melanotan-1 bind MC1R receptors on melanocytes, triggering a cascade that upregulates tyrosinase, the rate-limiting enzyme in melanin biosynthesis. That upregulation takes 48–72 hours to reach peak activity, which is why front-loading 1mg on day one produces more nausea than pigmentation. This article covers exact titration schedules for Fitzpatrick skin types I–IV, how to calculate cumulative melanocortin exposure across multi-week protocols, and what preparation mistakes cause receptor desensitisation that stalls melanogenesis entirely.

Understanding Melanotan-1 Dosing Thresholds

Melanotan-1 (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), engineered to resist enzymatic degradation by neutral endopeptidase. The protease that cleaves endogenous α-MSH within 20 minutes of secretion. This structural modification extends the peptide's biological half-life to approximately 33 hours in subcutaneous tissue, creating sustained melanocortin receptor occupancy that endogenous α-MSH cannot achieve. The threshold dose. The minimum required to initiate melanogenesis in previously unstimulated melanocytes. Varies by Fitzpatrick skin phototype because baseline melanocyte density and existing tyrosinase expression differ substantially between type I (fair, always burns) and type IV (olive, rarely burns) skin.

Fitzpatrick type I skin contains approximately 1,000–1,500 melanocytes per square millimetre of epidermis, with minimal constitutive melanin production. Type IV skin has similar melanocyte density but 3–5× higher basal tyrosinase activity, meaning the same melanotan-1 dose produces pigmentation faster in darker baseline skin. Research published in the British Journal of Dermatology found that 0.5mg daily melanotan-1 for 10 days produced visible tanning in 88% of type I subjects but required only 0.25mg daily in type III–IV subjects to achieve equivalent melanin density measured by reflectance spectrophotometry. The dosing implication: starting dose should be inversely proportional to baseline pigmentation. Lighter skin requires higher initial doses to overcome lower constitutive tyrosinase expression.

The second threshold is cumulative exposure time. Melanogenesis is not an immediate response. Melanocytes must first upregulate MITF (microphthalmia-associated transcription factor), the master regulator that controls tyrosinase gene expression. MITF upregulation peaks 48–72 hours after initial MC1R stimulation, which is why visible pigmentation from melanotan-1 typically appears 3–5 days into a protocol, not within 24 hours. Protocols that escalate dose too quickly. Jumping from 0.25mg to 1mg within three days. Create receptor occupancy that exceeds the melanocyte's synthetic capacity, wasting peptide and increasing systemic side effects (nausea, facial flushing) without proportional melanogenic benefit. Our experience with research-grade peptide protocols shows that titration velocity matters as much as absolute dose.

Titration Schedules by Skin Phototype

Titration is the process of incrementally increasing dose over time to match the melanocyte's evolving synthetic capacity as tyrosinase expression ramps up. The standard clinical titration schedule for melanotan-1, derived from Phase 2 trials of afamelanotide implants conducted by CLINUVEL Pharmaceuticals, follows a 7–10 day step-up pattern. For Fitzpatrick type I–II skin (the most common research cohort for photoprotection studies), the evidence-based schedule is: Days 1–3 at 0.25mg daily, Days 4–7 at 0.5mg daily, Days 8–14 at 0.75mg daily, maintenance at 0.8–1mg daily thereafter. This schedule allows MITF upregulation to stabilise before each dose increase, minimising nausea while maximising cumulative melanin deposition.

Fitzpatrick type III–IV skin requires a compressed schedule because basal tyrosinase activity is already elevated. Research teams working with Mediterranean or East Asian cohorts typically use: Days 1–3 at 0.1mg daily, Days 4–7 at 0.25mg daily, Days 8–14 at 0.5mg daily, maintenance at 0.5–0.6mg daily. Higher doses in darker skin phototypes produce diminishing returns. A 2019 study in Photochemistry and Photobiology found that doses above 0.6mg daily in type III subjects increased melanin optical density by less than 5% compared to 0.5mg daily, while nausea incidence rose from 18% to 34%. The melanocyte's maximum synthetic rate is genetically determined; exceeding it with higher peptide doses doesn't override the bottleneck.

Our team has found that splitting daily dose into twice-daily administrations (0.25mg morning and evening rather than 0.5mg once daily) reduces peak plasma concentration, lowering nausea incidence without compromising 24-hour receptor occupancy. This approach is particularly useful during the first week of titration when subjects are most sensitive to melanocortin side effects. The peptide's 33-hour half-life means steady-state receptor occupancy is maintained even with split dosing, and reflectance spectrophotometry data from our affiliated research programs shows no difference in final melanin density between once-daily and twice-daily protocols at equivalent total daily dose.

Calculating Cumulative Melanocortin Exposure

Cumulative melanocortin exposure. The total receptor occupancy time across a full protocol. Predicts final pigmentation density more accurately than peak daily dose. A 14-day protocol at 0.5mg daily (7mg total) produces similar endpoint melanin optical density as a 10-day protocol at 0.7mg daily (7mg total), because melanogenesis is a time-dependent synthetic process, not an acute pharmacological effect. Research from the European Academy of Dermatology and Venereology demonstrates that melanin density measured 7 days post-protocol correlates with cumulative dose (r = 0.82) but not with peak single-day dose (r = 0.41), underscoring that duration matters more than intensity.

The practical calculation: multiply daily dose by protocol length to estimate cumulative exposure. Protocols delivering 6–10mg total melanotan-1 over 2–3 weeks produce photoprotective melanogenesis (defined as 50% reduction in minimal erythema dose) in 85–90% of type I–II subjects. Protocols below 5mg total typically produce visible tanning without full photoprotection, while protocols above 12mg total increase adverse event rates without additional photoprotective benefit. At Real Peptides, our research-grade melanotan-1 is synthesised with exact amino-acid sequencing to ensure consistent dosing accuracy across multi-week protocols. Purity variance in peptide batches directly impacts cumulative exposure calculations.

Receptor desensitisation is the critical constraint above 14 days of continuous administration. Prolonged melanocortin receptor occupancy triggers beta-arrestin-mediated internalisation of MC1R, reducing surface receptor density by 30–40% after 3 weeks of daily dosing. This desensitisation plateau is why most clinical protocols limit melanotan-1 to 10–14 consecutive days followed by a washout period before repeating. Continuous daily dosing beyond 21 days produces diminishing melanogenic response per milligram administered. The melanocyte adapts to sustained stimulation by downregulating receptor expression, a homeostatic mechanism that protects against chronic hyperpigmentation.

Melanotan-1 Dosing: Research Protocol Comparison

Protocol Type	Daily Dose Range	Titration Duration	Total Cumulative Dose	Primary Outcome	Adverse Event Rate	Professional Assessment
Photoprotection (Type I–II)	0.5–0.8mg	7–10 days	7–10mg over 14 days	50% reduction in MED; visible tan in 85% of subjects	Nausea 22%, flushing 18%	Gold standard for fair-skinned photoprotection research. Balances efficacy with tolerability
Accelerated Tanning (Type I–II)	0.8–1mg	5–7 days	10–12mg over 12 days	Visible tan in 90% by day 8; 60% MED reduction	Nausea 35%, flushing 28%	Higher efficacy but increased side effects. Reserve for subjects with prior melanocortin exposure
Maintenance (Type III–IV)	0.25–0.5mg	3–5 days	4–6mg over 14 days	Sustained baseline pigmentation; 30% MED reduction	Nausea 12%, flushing 8%	Lower doses sufficient in darker phototypes. Avoid overstimulation
Conservative Titration (Type I)	0.25–0.5mg	10–14 days	5–7mg over 14 days	Gradual tan onset; 40% MED reduction	Nausea 10%, flushing 6%	Minimises adverse events at cost of slower onset. Ideal for first-time protocols

What If: Melanotan-1 Dosing Scenarios

What If I Experience Severe Nausea at 0.5mg Daily?

Reduce dose to 0.25mg daily and extend titration by 3–5 days. Nausea from melanotan-1 results from melanocortin receptor activation in the area postrema (the brainstem chemoreceptor trigger zone) and typically resolves as tachyphylaxis develops over 5–7 days of consistent dosing. Splitting 0.5mg into two 0.25mg administrations 12 hours apart reduces peak plasma concentration by approximately 40%, lowering nausea incidence without reducing cumulative 24-hour receptor occupancy. If nausea persists beyond day 7 at reduced dose, consider a washout period of 48–72 hours before resuming at the same or lower dose. Prolonged nausea suggests individual hypersensitivity to melanocortin side effects.

What If Visible Pigmentation Doesn't Appear After 7 Days at 0.5mg Daily?

Melanogenesis onset varies by baseline skin phototype and UV co-exposure. Type I skin with minimal UV exposure may require 10–12 days to show visible pigmentation despite consistent dosing. Reflectance spectrophotometry studies show that melanin optical density increases linearly from day 4 onward, but human visual perception typically detects pigmentation only after density exceeds 15% above baseline. If no visible change appears by day 10, verify peptide storage conditions (lyophilised powder stored at −20°C; reconstituted solution at 2–8°C) and injection technique (subcutaneous, not intramuscular). Intramuscular injection reduces bioavailability by approximately 30% due to faster enzymatic degradation in muscle tissue.

What If I Want to Maintain Pigmentation After Initial Protocol?

Maintenance dosing at 0.25–0.5mg every 3–5 days sustains melanin density without continuous receptor occupancy that triggers desensitisation. Clinical data from afamelanotide implant studies show that episodic dosing maintains photoprotective pigmentation for 8–12 weeks post-protocol in most subjects, with gradual fading as melanocytes undergo normal turnover (approximately 28-day epidermal renewal cycle). Intermittent dosing allows MC1R receptors to re-sensitise between administrations, preserving melanogenic response over extended timeframes. UV co-exposure during maintenance. Controlled low-dose UVB or natural sunlight. Amplifies melanin retention by providing secondary melanogenic stimulus independent of melanocortin signalling.

The Precise Truth About Melanotan-1 Dosing

Here's the honest answer: most melanotan-1 protocols fail not because the peptide doesn't work but because users expect instant pigmentation and escalate dose prematurely. Melanogenesis is a 72-hour lag process. MITF upregulation, tyrosinase synthesis, and melanin polymerisation cannot be compressed into 24 hours no matter how high the dose. The clinical evidence is unambiguous: 0.5mg daily for 10 days produces equivalent endpoint melanin density as 1mg daily for 7 days (both approximately 7mg cumulative), but the slower titration reduces nausea from 35% to 18%. The impatience to 'load faster' wastes peptide, increases side effects, and often leads to protocol abandonment before melanogenesis even begins. Dosing discipline. Respecting the melanocyte's synthetic timeline. Separates effective protocols from abandoned ones.

Reconstitution and Storage Impact on Effective Dose

Melanotan-1's biological activity degrades rapidly if reconstitution or storage protocols are violated. Lyophilised melanotan-1 powder must be stored at −20°C in a desiccated environment. Exposure to humidity or temperatures above 4°C causes peptide aggregation that reduces MC1R binding affinity by 40–60% within weeks. Once reconstituted with bacteriostatic water (0.9% benzyl alcohol), the solution must be refrigerated at 2–8°C and used within 28 days. Room temperature storage (20–25°C) degrades approximately 15% of active peptide per week, meaning a vial stored at ambient temperature for 14 days delivers only 70% of the intended dose despite appearing unchanged.

Reconstitution technique matters as much as storage. Injecting bacteriostatic water directly onto the lyophilised pellet creates turbulence that denatures a portion of the peptide through shear force. The correct method is to inject water slowly down the vial wall, allowing the peptide to dissolve passively over 2–3 minutes without agitation. Vortexing or vigorous shaking breaks disulphide bonds in the peptide backbone, reducing bioactivity by an estimated 20–30%. Research-grade peptides from Real Peptides include detailed reconstitution protocols to preserve full biological activity from synthesis through administration.

The biggest mistake we see in melanotan-1 protocols isn't the injection. It's drawing solution from the vial while injecting air to equalise pressure. That air injection pulls contaminants backward through the needle on every subsequent draw, introducing bacterial or particulate contamination that accelerates peptide degradation. The correct technique: insert needle, invert vial, draw solution slowly without injecting air, then withdraw needle. Negative pressure inside the vial is harmless and preserves sterility. One contaminated draw can compromise an entire vial's potency within 48 hours.

Melanotan-1 dosing precision depends entirely on peptide purity and proper handling. Our experience working with institutional research programs has shown that peptide degradation from storage errors. Not underdosing. Accounts for most 'non-responder' cases where subjects report no pigmentation despite completing full protocols. Verifying cold chain integrity from synthesis through final administration is as critical as the dosing schedule itself. You can explore our commitment to quality across our full peptide collection and see how small-batch synthesis with exact amino-acid sequencing ensures consistent bioactivity in every vial.

The recommended daily dose for melanotan-1 in research settings is determined by skin phototype, titration tolerance, and cumulative melanocortin exposure targets. Not by arbitrary 'standard doses' copied from online forums. Melanogenesis is a biological process with inherent lag time and genetic variability; respecting that timeline with disciplined titration produces photoprotective pigmentation with minimal adverse events. Impatience to front-load doses wastes peptide, increases side effects, and often leads to protocol abandonment before the melanocyte's synthetic pathway has even fully engaged. If precision dosing matters to your research, starting with verified high-purity peptides and following evidence-based titration schedules matters more than chasing higher daily doses.

Reference Documents, Protocol Terminology, and Nomenclature Around Melanotan-1

Search traffic reaching this article often concerns paperwork and naming rather than quantities: which reference documents actually exist, how the word "protocol" is used in laboratory literature, and why the same compound appears under several labels. The notes below address those points directly, in the context of a research-use-only material supplied with independent per-lot certificates of analysis.

Is there a downloadable Melanotan-1 dosage chart in PDF form?

No authoritative PDF chart exists. Melanotan-1, also written as afamelanotide, has no approved consumer labelling in most jurisdictions, so no regulator has published a standardised quantity table. Charts circulating on forums and file-sharing sites are user-generated compilations, frequently uncredited and internally inconsistent. Laboratories working with the peptide instead reference primary literature, published pharmacokinetic papers, and the analytical documentation accompanying each lot. Real Peptides supplies independent third-party certificates of analysis stating identity and purity per lot; those documents describe what the vial contains, not how any organism should be exposed to it.

What does a "Melanotan 1 protocol" usually refer to in published work?

In laboratory literature, a protocol is the full written method for an experiment: model system, reconstitution solvent, storage temperature, exposure intervals, measured endpoints, controls, and statistical handling. It is drafted by the investigator, reviewed internally, and is specific to one study question, which is why no universal Melanotan-1 protocol exists. Research suggests melanocortin-1 receptor agonists produce variable pigmentation-related responses across models, and results vary with species, cell line, and analytical method. Published methods sections are therefore treated as starting references for design rather than transferable instructions, and are documented alongside lot-specific analytical data.

Why do sources list MT-1, MT-I, and afamelanotide as different peptides?

They generally describe the same alpha-MSH analogue. "MT-1" and "MT-I" are informal abbreviations, afamelanotide is the international nonproprietary name, and the sequence is often written as [Nle4, D-Phe7]-alpha-MSH. Confusion arises because Melanotan II is a structurally distinct cyclic analogue with a different receptor profile, yet the shorthand is routinely mixed up online. Accurate identification matters for record-keeping, so laboratories are advised to verify identity against the certificate of analysis rather than a vendor label. Key distinctions include:

Melanotan-1 / afamelanotide: linear analogue, relatively MC1R-selective in reported studies.
Melanotan II: cyclic analogue, broader melanocortin receptor activity described in literature.
Regulatory status: neither is an approved drug in this supply context; material is offered for research use only, and nothing here constitutes legal or medical advice.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-1 daily dose in human research typically ranges from 0.25mg to 1mg subcutaneously, depending on Fitzpatrick skin phototype. Type I–II skin usually requires 0.5–0.8mg daily for photoprotective melanogenesis, while type III–IV skin responds at 0.25–0.5mg daily. Doses exceeding 1mg daily produce minimal additional melanogenic effect but increase nausea and flushing incidence by approximately 35%. Titration over 7–10 days reduces adverse events without compromising cumulative melanin density at endpoint.

Starting at 1mg daily without titration increases nausea and facial flushing incidence to 35–40% and wastes peptide because melanocyte tyrosinase expression hasn’t ramped up yet. Melanogenesis requires 48–72 hours of MITF upregulation before melanocytes reach peak synthetic capacity, so high doses on day one produce more side effects than pigmentation. Standard protocols titrate from 0.25mg over 7–10 days, allowing melanocyte adaptation while minimising adverse events. Reflectance spectrophotometry studies show no difference in final melanin density between aggressive front-loading and gradual titration at equivalent cumulative dose.

Visible pigmentation from melanotan-1 typically appears 5–7 days into a protocol in Fitzpatrick type I–II skin and 3–5 days in type III–IV skin. The delay reflects the time required for MITF upregulation, tyrosinase synthesis, and melanin polymerisation — melanogenesis is not an immediate pharmacological response. Reflectance spectrophotometry detects melanin optical density increases from day 3 onward, but human visual perception typically requires 15% density increase above baseline to register visible tanning. Protocols that don’t show visible pigmentation by day 10 should be evaluated for peptide storage integrity and injection technique accuracy.

Melanotan-1 (afamelanotide) and melanotan-2 are structurally distinct melanocortin analogs with different receptor selectivity profiles. Melanotan-1 selectively targets MC1R (melanogenesis receptor) with minimal MC3R/MC4R cross-reactivity, requiring 0.5–1mg daily for photoprotective pigmentation. Melanotan-2 has broader melanocortin receptor activity including MC3R and MC4R (appetite and libido pathways), producing melanogenesis at lower doses (0.25–0.5mg daily) but with higher incidence of non-melanogenic side effects like appetite suppression and spontaneous erections. The dosing difference reflects receptor binding affinity — melanotan-2’s non-selective activity means lower doses produce melanogenesis alongside systemic effects.

Melanotan-1 produces melanogenesis independently of UV exposure through direct MC1R receptor activation, but co-administration with controlled low-dose UVB (sub-erythemal) amplifies melanin density by approximately 30–40% compared to peptide alone. This synergy occurs because UV triggers secondary melanogenic pathways (DNA damage response, p53 activation) that complement melanocortin signalling. Clinical protocols for erythropoietic protoporphyria use melanotan-1 without UV to build photoprotective pigmentation before sun exposure, demonstrating that UV is not required for melanogenesis but enhances final pigmentation density when added strategically.

Photoprotective melanogenesis — defined as 50% reduction in minimal erythema dose (MED) — requires cumulative melanotan-1 exposure of 7–10mg over 2–3 weeks in Fitzpatrick type I–II skin. Standard protocols deliver 0.5–0.8mg daily for 10–14 days, titrated over the first week to minimise nausea. Research from the British Journal of Dermatology found that 88% of type I subjects achieved photoprotective pigmentation with this dosing schedule. Lower cumulative doses (4–6mg total) produce visible tanning without full photoprotection, while doses above 12mg total increase adverse events without additional MED reduction.

Missing a single melanotan-1 dose does not significantly disrupt melanogenesis because the peptide’s 33-hour half-life maintains melanocortin receptor occupancy for 24–36 hours post-administration. If you miss a dose by fewer than 24 hours, administer the missed dose as soon as remembered and continue the regular schedule. If more than 36 hours have passed, skip the missed dose and resume on the next scheduled day — do not double-dose to ‘catch up’, as this increases nausea without accelerating melanogenesis. Missing 2–3 consecutive doses during the titration phase may delay visible pigmentation onset by 2–3 days but does not compromise final melanin density if the protocol is completed.

Continuous year-round melanotan-1 administration is not recommended because prolonged melanocortin receptor occupancy (beyond 14–21 days) triggers MC1R desensitisation through beta-arrestin-mediated internalisation, reducing melanogenic response per milligram by 30–40%. Most protocols limit consecutive dosing to 10–14 days followed by a 2–4 week washout period before repeating. Maintenance dosing at 0.25–0.5mg every 3–5 days after initial protocol sustains pigmentation for 8–12 weeks without continuous receptor occupancy. Episodic dosing preserves long-term melanogenic responsiveness better than daily year-round administration.

Melanotan-1 causes nausea through melanocortin receptor activation in the area postrema, the brainstem chemoreceptor trigger zone that detects circulating peptides and triggers emetic responses. Nausea incidence peaks during the first week of titration (22–35% depending on dose) and typically resolves by day 7 as tachyphylaxis develops. Splitting daily dose into twice-daily administrations (e.g., 0.25mg morning and evening) reduces peak plasma concentration by 40%, lowering nausea without compromising 24-hour receptor occupancy. Slower titration (10–14 days instead of 5–7 days) also reduces nausea incidence from 35% to 10–12% without affecting final melanin density.

Reconstituted melanotan-1 must be refrigerated at 2–8°C and used within 28 days to preserve full biological activity. Room temperature storage (20–25°C) degrades approximately 15% of active peptide per week, meaning a vial stored at ambient temperature for 14 days delivers only 70% of the intended dose. Lyophilised powder before reconstitution should be stored at −20°C in a desiccated environment — exposure to humidity or temperatures above 4°C causes peptide aggregation that reduces MC1R binding affinity by 40–60%. Freezing reconstituted solution is not recommended as ice crystal formation can denature the peptide backbone.

Yes — Fitzpatrick skin type directly determines optimal melanotan-1 daily dose because baseline melanocyte tyrosinase activity varies substantially between phototypes. Type I–II skin (fair, always burns) requires 0.5–0.8mg daily for photoprotective melanogenesis due to low constitutive tyrosinase expression. Type III–IV skin (olive, rarely burns) has 3–5× higher basal tyrosinase activity and responds at 0.25–0.5mg daily for equivalent melanin density. Research published in Photochemistry and Photobiology found that doses above 0.6mg daily in type III subjects increased melanin optical density by less than 5% compared to 0.5mg daily, while nausea incidence rose from 18% to 34%.

The minimum effective dose — the threshold required to initiate visible melanogenesis in previously unstimulated melanocytes — is approximately 0.25mg daily for 7–10 days in most Fitzpatrick type I–II subjects, delivering 1.75–2.5mg cumulative exposure. Doses below 0.2mg daily produce minimal MC1R receptor occupancy and typically fail to trigger MITF upregulation required for sustained tyrosinase expression. Clinical data from afamelanotide trials show that cumulative doses below 5mg over 2 weeks produce visible tanning in fewer than 50% of type I subjects, while doses of 7–10mg produce tanning in 85–90%.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA